Wieso kauft man solche Aktien?
1 extracted signal · 0 resolved · 1 still active
Wir Lieben Aktien GmbHIndependent analyst profile- Source published
- 14 Oct 2026, 11:33 UTC
- Recorded by Tahlil Plus
- 14 Oct 2026, 14:26 UTC
AI-generated source summary
The analysis focuses on Microbot Medical Inc. (MBOT), a medical technology company. The current price is 1.02, with a reported performance showing a significant loss of -64.86% and a position value of 664.84. The stock has experienced a prolonged downtrend for approximately 20 years, indicating a consistent bearish market. The speaker highlights that the stock is currently in an all-time low region and, despite potential stabilization at these low levels, it does not constitute a good stock. The large price movements are attributed to an extremely high risk class. The company's history shows a rise from $1 to $5, which, while sounding significant, is put into perspective by the overall bearish trend and the current low valuations. The speaker's view is that the stock is essentially 'müll' (trash) due to its persistent downward trajectory and high-risk nature, suggesting a target price around 0.57, with a clear indication that a move above 1.35 would invalidate this bearish outlook.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Live evaluation in progress
1 signal remains active.
Wir Lieben Aktien GmbH
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.